David Freyer, DO, MS News

A multi-center clinical trial demonstrates how new reporting tools help symptom management and intervention for children receiving cancer treatment.

Hunter never let his acute lymphoblastic leukemia diagnosis define him—but today, he proudly wears the title “survivor” in support of cancer research.

A new survey endorses the value of cancer survivorship care but finds that many adult patients aren’t accessing it.

A key study led by Dr. David Freyer showed that sodium thiosulfate prevented cisplatin-related hearing loss in children and led to therapy approval.

A CHLA clinical trial finds that N-acetylcysteine may be a promising next-generation therapy to reduce the risk of cisplatin-induced hearing loss.

A CHLA oncologist led a pivotal clinical trial leading to the approval of the first drug to prevent cisplatin hearing loss in children.

A Children’s Hospital Los Angeles researcher uncovers discrepancies between doctor reports and child self-reports about the side effects of cancer treatment.

Researchers have been delving deeper to better understand long-term cancer survival and quality of life for adolescent and young adult patients.

Ellen Chang, MD, MS Ellen is the Adolescent and Young Adult (AYA) Oncology/Survivorship fellow. She is passionate about improving long-term health outcomes in childhood cancer survivors. “In medical